Clinical Outcomes of Advanced Cancer Patients Treated with Immune-Checkpoint Inhibitors: From the Inflamed Tumor to the Inflamed Patient

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 686

Special Issue Editor

E-Mail Website
Guest Editor
Medical Oncology Unit, University Hospital of Parma, Parma, Italy
Interests: renal cell carcinoma; urothelial carcinoma; immunotherapy

Special Issue Information

Dear Colleagues,

The new immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized oncology in the last decade. Despite outstanding and previously unpredictable results achieved for several solid tumors, a non-negligible rate of cancer patients still do not respond to ICIs, and there are no robust predictors of such primary refractoriness. The reasons for the lack of response to immune checkpoint blockades, together with the predictors of marked immune responsiveness, should be searched in the individual themselves as opposed to in his/her tumor, as the target of ICIs is no longer the tumor cell but the T-effector cells. In the patient-centric view, the tumor immune microenvironment (TIME) modifications and its immunogenicity should be interpreted as the consequence of a systemic immune reaction provided by the host. Dysmetabolic conditions, the use of concomitant drugs, microbiota alterations, acute or chronic viral infections, surgical procedures, and a wide range of life events (e.g., pregnancy) may be responsible for different immune footprints on single individuals. The present Special Issue aims to collect evidence about these epiphenomena of an “inflamed patient”, whose tumor is likely to have been favored by immune suppression and to respond to an ICI-induced reversal of immune exhaustion.

Dr. Sebastiano Buti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • immunotherapy
  • immune checkpoint inhibitor
  • immunogenicity
  • inflammation
  • inflamed tumor
  • inflamed patient
  • immune response
  • outcome prediction
  • prognosis
  • cancer patients
  • solid tumors

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop